SFS
BLRX

Sowell Financial Services’s BioLineRX BLRX Stock Holding History

Sowell Financial Services’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5
Closed -$1K – 3112
2020
Q4 		$1K Buy
+5
New +$437 ﹤0.01% 2549

Other funds holding BLRX

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

Sowell Financial Services's BLRX Position: Q1 2021 in Review

Sowell Financial Services sold out of BioLineRX (BLRX) in Q1 2021, closing a stake of 5 shares — an estimated $1K sold.

Sowell Financial Services first reported a position in BLRX in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 28 funds tracked by Wall St. Rank hold BLRX as of Q1 2021.

  • Sowell Financial Services reported no remaining BioLineRX position as of Q1 2021 after selling out during the quarter.
  • Sowell Financial Services sold 5 BioLineRX shares in Q1 2021, an estimated $1K.
  • Sowell Financial Services first reported a position in BioLineRX in Q4 2020 and held it in 1 quarter.
  • Sowell Financial Services's BioLineRX position peaked at $1K in Q4 2020.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q1 2021.

Based on Sowell Financial Services's 13F filing for Q1 2021, filed 7 May 2021.